Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 2Endocrine 2

Conditions

Colorectal Neoplasms 445Carcinoma, Non-Small-Cell Lung 224Breast Neoplasms 189Ovarian Neoplasms 167Glioblastoma 156Neoplasms 126Carcinoma, Hepatocellular 124Rectal Neoplasms 112Colonic Neoplasms 107Neoplasm Metastasis 104Brain Neoplasms 96Lung Neoplasms 91Fallopian Tube Neoplasms 85Carcinoma, Renal Cell 71Glioma 69Pancreatic Neoplasms 54Gliosarcoma 43Melanoma 42Liver Neoplasms 42Uterine Cervical Neoplasms 40Stomach Neoplasms 37Adenocarcinoma of Lung 36Recurrence 33Astrocytoma 30Endometrial Neoplasms 27Carcinoma, Ovarian Epithelial 27Triple Negative Breast Neoplasms 26Prostatic Neoplasms 22Kidney Neoplasms 22Esophageal Neoplasms 21

Interventions

Paclitaxel 10trametinib 9dabrafenib 9pembrolizumab 5lenvatinib 5fosbretabulin 4Sorafenib 4Radiotherapy, Intensity-Modulated 4Doxorubicin 4Radiotherapy 3Cisplatin 3pazopanib 2efatutazone 2combretastatin 2cobimetinib 2cemiplimab 2atezolizumab 2aldesleukin 2Vemurafenib 2Trastuzumab 2Taxes 2Nivolumab 2Gefitinib 2Filgrastim 2Everolimus 2Docetaxel 2Carboplatin 2Bevacizumab 2zimberelimab 1vandetanib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Thyroid Carcinoma, Anaplastic × Bevacizumab × Clear all
NCT03181100 2026-01-09

Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cancer

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
50 enrolled
EndocrineHead & Neck

Thyroid Neoplasms, Thyroid Carcinoma, Anaplastic

NCT00804830 2018-08-28

Avastin and Doxorubicin Postoperatively for Patients With Anaplastic Thyroid Cancer

Region Skane

Phase 2 Terminated
15 enrolled
EndocrineHead & Neck

Carcinoma, Neoplasm Metastasis, Thyroid Neoplasms, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡